Colorado Clinical Trials Report — April 2026

For Colorado residents considering participation in clinical research, April 2026 presents a critical window to act, especially for studies nearing their enrollment deadlines. Across the state, a significant number of trials are preparing to close, meaning opportunities to join are quickly diminishing. Specifically, 127 clinical trials are slated to conclude enrollment within the next 90 days. This urgency extends to healthy volunteers, with 23 of these rapidly closing studies still actively seeking individuals without specific health conditions. If you've been contemplating contributing to medical science, now is the time to explore these options before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various types of cancer, neurological disorders, and chronic conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer
• Myasthenia gravis
• Asthma
• Headache
• Mental health conditions
• Migraine
• Heart failure
• B-cell acute lymphoblastic leukemia
• Cystic fibrosis
• Deep venous thrombosis

Major Advancements and New Opportunities Emerge in April

This month brings a fresh wave of research opportunities to Colorado, including significant Phase 2 and 3 studies from major pharmaceutical companies and leading research institutions. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a spectrum of health challenges.

Among the 13 new trials launched this month, several stand out for their potential impact and the credibility of their sponsors:

• Incyte Corporation is sponsoring NCT07522073, a Phase 3 study evaluating chemotherapy with or without an investigational drug, INCB161734, for previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This crucial oncology trial aims to enroll 588 participants, offering a new avenue for those battling this aggressive cancer.
• For individuals with Alport Syndrome, Eloxx Pharmaceuticals, Inc. is initiating the "EXACT Study," NCT07523581. This Phase 2, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of exaluren in Alport Syndrome patients with nonsense mutations in COL4A3/4/5 genes. The study targets 24 patients aged 12 and older.
• The VA Office of Research and Development is leading NCT07513805, focusing on the "Implementation of Routine Walking Speed Measurements in Older Veterans." This large-scale study, with 10,500 participants, recognizes walking speed as a powerful predictor of health outcomes in older adults, aiming to provide unique insights into physical function and healthcare needs.
• Children's Hospital Medical Center, Cincinnati is launching the "Asthma Ctrl SMART Trial," NCT07512622. This study, involving 389 participants, will examine the effectiveness of a mobile health (mHealth) intervention called Asthma Ctrl in improving adherence to daily inhaled corticosteroids among adolescents with asthma.

Beyond these notable studies, new trials are exploring a range of conditions, offering diverse opportunities for participation. This month's new trials are targeting:

• Advanced/metastatic colorectal adenocarcinoma
• Aging
• Alport syndrome, autosomal recessive
• Alport syndrome, x-linked
• Asthma chronic
• Asthma in children
• Congenital anomaly
• Device performance
• Failure of Fontan type circulation
• Fall risk

The types of interventions being studied are varied, with drug trials leading the way, accounting for 5 of the new trials. Device studies represent 4 new trials, behavioral interventions 3, and one other type of study.

Colorado's Research Footprint: Where Opportunities Are Growing

Colorado continues to be a hub for clinical research, with 1,766 clinical trials currently recruiting across 56 cities and 1,023 research sites statewide. While the state offers broad accessibility, new trial openings this month show a clear concentration in specific metropolitan areas.

Of the 13 new trials launched in April, the majority are located in the Denver metropolitan area:

• Aurora saw the highest number of new trials, with 7 opening.
• Denver added 3 new trials.
• Louisville introduced 2 new trials.
• Broomfield welcomed 1 new trial.

This geographic distribution highlights the continued growth of research infrastructure in and around Colorado's major population centers, making participation convenient for many residents.

Diverse Participation: Healthy Volunteers and Specific Demographics

Clinical trials are designed to include a wide range of individuals, ensuring that new treatments and interventions are safe and effective for diverse populations. Of the 13 new trials launched this month, 5 include children, and 8 are open to older adults, demonstrating a commitment to inclusive research.

For individuals without a specific medical condition, there are ample opportunities to contribute to medical advancements. 4 of the new trials this month are actively seeking healthy volunteers. Across Colorado, a total of 203 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research and helping to establish baseline data for new therapies.

Academic institutions and industry partners are both driving significant research efforts in Colorado. The University of Colorado, Denver, sponsored 2 of the new trials. Industry sponsors, including Incyte Corporation, Eloxx Pharmaceuticals, Inc., Bayer, Bial R&D Investments, S.A., All Health, Inc., and Occlutech International AB, are collectively behind 8 of the new studies this month. The VA Office of Research and Development and Children's Hospital Medical Center, Cincinnati, also contributed to the new trial landscape.

Looking ahead, the focus will remain on advancing these critical studies, particularly those in later phases, while continuing to expand opportunities for Coloradans to engage in the development of future medical solutions.